Bristol-Myers Squibb Company (BMY) Stock Analysis & Winston Score

Bristol-Myers Squibb is a large pharmaceutical company that discovers, makes, and sells prescription medicines. Its biggest products treat cancer, blood clots, and immune system diseases — with well-known drugs like Eliquis (a blood thinner), Opdivo (a cancer treatment), and Revlimid (a blood cancer drug). Hospitals, doctors, and patients in over 50 countries rely on these medicines. The company makes money by selling its drugs directly to hospitals, pharmacies, and healthcare distributors, often at high prices protected by patents. It operates globally, with the United States generating the majority of its revenue, and its $111 billion market cap makes it one of the larger drug companies in the world. The biggest risk Bristol-Myers Squibb faces is patent expiration — Revlimid has already begun losing patent protection, and several other key drugs face similar cliffs in the coming years, which could significantly reduce revenue unless new drugs successfully replace them.